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a b s t r a c t 
Background: Although the diffusion of novel synthetic opioids has become a worldwide phenomenon, their preva- 
lence of use in Italy seems to be limited. Existing national data is mainly derived by anamnestic surveyslacking 
of toxicological validation and not always disclosing the use of these compounds, which might remain under- 
diagnosed. 
Methods: an assessment of the metabolites of the main synthetic opioids on hair samples was carried out among 
patients admitted at the Addiction Treatment Unit of Trento. The analytical approach included: (a) screening 
by means of immunoenzymatic method for fentanyl, fentanyl analogs and oxicodone; (b) confirmation of the 
samples resulted positive for fentanyl and oxicodone by means of HPLC-MS/; (c) search and dosage detection of 
Tramadol by means of HPLC-MS/MS. 
Results: 3 out of 309 analysed samples were found positive: one was positive to Fentanyl and two to 4-ANPP. In 
the same cohort, 6 samples were also found positive for Oxycodone . Tramadol was searched in 189 samples and 
12 of them resulted positive. 
Discussion and conclusion: Those found positive were mainly young adults engaging in dangerous patterns of use 
and lacking awareness of risks. The phenomenon requires further consideration by health professionals. Training 
and more evidence-based information on synthetic opioids as well as other Novel Psychoactive Substances (NPS) 




























In recent years, the use of synthetic opioids has largely increased
mong the general population ( Raithelhuber, 2017 ). The rapid and pro-
ressive spread of this phenomenon since the mid-to late 1990s can be
ostly attributed to two distinct elements. The first one to consider
s a general and increasing use of these molecules with highly addic-
ive potential in clinical settings, including their prescriptions for the
reatment of acute and, most of all, chronic, persistent and severe pain
 Phillips, 2017 ). The latter often underestimate the risks of misuse, de-
endence and addiction. ∗ Corresponding author at: Dirigente Medico, Specialista in Psichiatria, SerD Trento
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nder the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/The second relevant element about the spread of the use of synthetic
pioids is due to its recreational use. These highly potent molecules
re easily available at low costs and its consumption can represent a
ess stigmatizing condition to the user compared to other illegal drugs
 Kuczy ń ska et al. 2018 ; Lovrecic et al. 2019 ). Despite prescription opi-
ids are regularly used in clinical settings for the treatment of chronic
ain, among other conditions, they may expose users to serious health
hreats. As part of this phenomenon, an exponential increment in the
se of fentanyl and its derivatives has been documented at the global
evel ( United Nations Office on Drugs and Crime, 2017 ). Fentanyl, a clin-
cally well-known agent to treat chronic pain and for anesthesia, is a very, via Gocciadoro 47/49, Trento, Italy. 
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otent opioid approved for human use. Its prescription has been regu-
ated internationally since 1964. Since then, a large number of highly
otent derivatives have emerged in the licit and illicit drug market
e.g. alfentanyl, sulfentanyl, carfentanil), exposing users to considerable
ealth risks. A small amount of these drugs is enough to cause overdoses
nd much larger doses of Naloxone, than those required in case of heroin
verdoses, are necessary to reverse this condition. Therefore, episodes
f overdose are often fatal ( Mohr et al., 2016 ; Armenian et al., 2018 ;
oore et al., 2008 ). 
Fentanyl and derivates are often synthesized in clandestine labora-
ories and sold illicitly either on street or online on illegal, recreational
rug markets. As a result, severe adverse outcomes, including over-
ose mortality have been reported across the Europe ( Ciccarone, 2019 ;
oorob, 2019 ; Dai et al., 2019 ) and a few cases of intoxication and
eath have also been reported in Italy prompting a change in legisla-
ion ( Gerace et al., 2018 ; Dipartimento Politiche Antidroga, 2021 ). 
The aim of this study was to evaluate the prevalence of use of
opular synthetic opioids (fentanyl, oxycodone and tramadol) among
 cohort of patients in treatment at the Addiction Treatment Unit of
rento. 
We investigated the presence of the main synthetic opioids in hair
amples collected from a number of patients in treatment for addiction.
creening was undertaken for fentanyl, oxycodone and tramadol. While
entanyl was chosen to gain a better understanding of its diffusion in the
ational territory, tramadol and oxycodone were chosen because some
atients from our Unit declared in clinical interviews that they had used
hem for analgesic purposes. 
aterials and methods 
tudy sample 
All tested subjects were in treatment for addiction, as per criteria
escribed in the Diagnostic and Statistical Manual of Mental Disorders
DSM–5). All samples were obtained as part of the routinary toxicologi-
al screening, for which all participants gave specific consent. The time
rame considered was 3 months (1st December 2018-1st March 2019).
xclusion criteria included absence of head hair, recent cosmetic treat-
ent, recent (one month) hair test, discontinuity of interaction with the
rento Addiction Unit during the three-month trial. The mean age of
he tested population was 39.6 years, with a ratio male: female = 6:1.
ll samples were analyzed in their entire length, up to a maximum of
he proximal 3 cm, since the study aimed at exploring the intake of drugs
n the three months prior the collection. 
hemicals and reagents 
Certified standards (1 mg/mL) of fentanyl, fentanyl-D5, tra-
adol and oxycodone were supplied by LGC Standards (Milan, Italy). A
ixture of diluted secondary standards (0.50 mg/L) of fentanyl metabo-
ites and analogs (norfentanyl, acetylfentanyl, furanyl-ethilfentanyl,
ufentanyl, carfentanyl, alfentanyl, carboxy- valerylfentanyl, acetyl-
orfentanyl, trans -3-methyl-norfentanyl, cis -3-methyl-norfentanyl,
ethoxy-acetyl-norfentanyl, furanyl-norfentanyl, butyryl-norfentanyl,
espropionil- para -fluorofentanyl, carboxy-butyrylfentanyl, phenyl-
cetylfentanyl, 4-ANPP, butyryl-fentanyl, beta-hydroxy-thiofentanyl)
ere supplied by Comedical (Trento, Italy). The Thermo-Scientific DRI
mmunometry reagents for fentanyl and oxycodone were distributed
y Instrumentation Laboratory S.p.A - Werfen (Milan, Italy). VMA-T
eagent, SLV-VMA-T wash solution, VMA-T KTZ calibrators, CTRL
MA-T and KTZ negative control, M3 reagent (R1 and R2), were
rovided by Comedical (Trento, Italy). The VMA-T FENT calibrator and
ontrol were prepared in the laboratory. 
All samples underwent routinary screening for common drugs
f abuse (methods not shown) and synthetic opioids (described as
ollows). 2 creening test for fentanyl and oxycodone 
309 hair samples, coming from the Addiction Centers from the
rovince of Trento (north of Italy), were collected and sent to the labo-
atory for routine investigations and clinical monitoring. For each sam-
le, 33mg of hair were finely chopped and washed with 1 ml of washing
olution SLV-VMA-T which was then aspirated and eliminated. Subse-
uently, 400 μL of VMA-T reagent was added to the samples; the tubes,
ermetically sealed with a screw cap, were incubated at 100°C for one
our ( Zoorob, 2019 ; De La Torre et al., 2010 ; Pichini et al., 2014 ). After
ooling at room temperature, the liquid extract was transferred in a cup
nd analyzed with a DRI immunometric screening test. During the test
or fentanyl, 25 mg of the extracted sample is reacted with 80 μl of R1
nd 80 μl of R2. The reading was at the wavelength of 340 nm. During
he oxicodone test, 13 μl of extracted sample is reacted with 90 μl of R1
nd 90 μl of R2. 
The analyses were performed on ILab-Taurus multiparametric an-
lyzer supplied by Instrumentation Laboratory S.p.A - Werfen (Milan,
taly). The immunometric methods were calibrated using the CAL VMA-
-FENT calibrators (fentanyl 0,000-0,015-0,030-0,060 ng / mg) and
AL VMA-T-KTZ (oxycodone 0.00-0.25-0.50-1.00-2.00 ng / mg). At
ach analytical session the controls CTRL VMA-T NEG (fentanyl 0.000
g / mg - oxycodone 0.00 ng / mg), CTRL VMA-T FEN (fentanyl 0.028
g / mg) and CTRL VMA-T KTZ (oxycodone 0.35 ng / mg) have been
ncluded. 
Based on available data in the literature obtained from real synthetic
pioids users ( Reisfiled, 2015 ; Stowe et al, 2019 ; Salomone et al, 2019 ),
amples with a concentration higher than 0,300 ng/mg for oxycodone
nd higher than 0,010 ng/mg for fentanyl were considered positive and
hen sent to the confirmation analysis. 
creening test for tramadol 
Among the 309 samples tested for fentanyl and oxycodone, a fur-
her analysis for tramadol was possible in 189 cases. These samples
ere therefore analyzed with a screening test by UPLC-MS/MS, after
he extraction with 100°C incubation in Reactive VMA-T, as for the other
creen tests. 50 μl of the extract were diluted in a vial with 450 μl of
i-distilled water. 
With the same procedure, the CAL-VMA-T KTZ calibrators (Tramadol
.00-0.25-0.50-1.00-2.00 ng / mg) and the CTRL VMA-T NEG controls
Tramadol 0.00 ng / mg) and CTRL-VMA-T KTZ (Tramadol 0.25 ng /
g) were diluted and analyzed. 
The UPLC-MS / MS analysis was conducted on the Acquity tool UPLC
 XEVO TQD (Waters Corporation), with a 1.8 μm UPLC HSS C18 Acquity
olumn, 2.1 × 150 mm. 
The mobile phase is composed of Ammonium Formate 5 mM 0.3%
ormic acid (solvent A) and acetonitrile (solvent B), flow 0.40 mL
 min. The transition considered (ESI + ) for the detection of Tra-
adol at the retention time of 2.16 minutes is 264.2 > 58.1 (quan-
ifier fragment): cone voltage 25 V, collision energy 15 V, tempera-
ure at the source 150°C, desolvation temperature 650°C, desolvation
as 1200 l/Hz. The samples with a concentration range higher than
,100 ng/mg were arbitrarily considered positive ( Verri et al, 2015 ;
intz et al, 2018 ; Johansen et al, 2020 ) and sent to a second analysis for
onfirmation. 
PLC-MS/MS confirmation analysis 
A further quantity of the hair samples that tested positive in the im-
unometric screening (for fentanyl and oxycodone) and the ones that
ested positive for tramadol in the LC-MS/MS screen test were submitted
o confirmation analysis by means of a fully in-house validated method.
ach sample was washed twice with methanol and once with diethyl
ther, then dried. 
25 mg of samples, calibrators and controls were added with 500 𝜇L
f M3 reagent and 10 𝜇L of Fentanyl D5 Internal Standard (0.10 mg/L)
nd incubated at 100°C for one hour 7 . 
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Table 1 
Summary of screening and confirmation results. 
Cut off 0,100 ng/mg 0,300 ng/mg 0,100 ng/mg 
Fentanyl Oxycodone Tramadol 
Number of samples 309 309 189 
Negative results 306 303 177 
Positive results 3 6 12 





















































Summary of all findings in hair samples positive to synthetic opioids. 
Gender Age Synthetic opioids Common drugs of abuse 
Male 38 Fentanyl, tramadol, oxicodone Heroin, cocaine 
Male 19 Fentanyl Heroin, THC 
Male 19 Fentanyl, tramadol Heroin, cocaine, MDMA. ketamine 
Male 26 Oxycodone Heroin, MDMA, amphetamines 
Female 60 Oxycodone Cocaine, THC 
Male 26 Oxycodone Heroin, cocaine 
Male 61 Oxycodone Cocaine, THC 
Female 50 Oxycodone Heroin, THC 
Male 29 Tramadol Heroin, cocaine, THC 
Male 55 Tramadol THC 
Female 52 Tramadol Heroin 
Male 42 Tramadol Heroin, cocaine 
Male 45 Tramadol Heroin, cocaine 
Male 32 Tramadol Heroin, cocaine 
Male 34 Tramadol Heroin, cocaine 
Male 42 Tramadol Heroin 
Male 23 Tramadol Heroin, cocaine 













































After cooling to room temperature, 100 μL of the extract was diluted,
n special vials, with 900 μL of bi-distilled water and 10 μL were injected
nto an instrument UPLC – MS/MS. 
The analyses were performed by using a Acquity UPLC-XEVO
QD (Waters Corporation) mass spectrometer, equipped with 1.8 μm,
.1 × 150 mm (ESI + ) Acquity UPLC HSS C18 column. The calibration
urve was built with a pool of negative keratin matrix samples, fortified
ith different certified concentrations at six different levels. Reference
nalytical standards and commercially available fortified samples were
dded as internal quality controls. 
For tramadol, the transitions considered at the retention time of 2.16
inutes is 264.2 > 58.1 (quantifier), cone voltage 25 V, collision energy
5 V, and 264.2 > 2461 (qualifier), cone voltage 25 V, collision energy
5 V; for oxycodone the transition considered at the retention time of
.19 minutes is 316.1 > 241.2 (quantifier) and 316.1 > 256.2 (quali-
er), cone voltage 35 V, collision energy 30 V. 
For fentanyl, the transition considered at the retention time of 2.93
inutes is 337.2 > 105.2 (quantifier) and 337.2 > 188.2 (qualifier),
one voltage 40 V, collision energy 35 V; for Fentanyl-D5 the transition
onsidered at the retention time of 2.92 minutes is 342.2 > 188.2 (quan-
ifier), Voltage Cone 25 V, Collision energy 15 V 12 . In the confirma-
ion method for fentanyl, also 4-ANPP was monitored. This compound
s either a precursor or a metabolite of several fentanyl analogues. The
onitored transitions were 281.2 > 105.0 (quantifier), cone voltage 22
, collision energy 32 V, and 281.2 > 188.0 (qualifier), cone voltage 22
, collision energy 14 V. 
esults 
Of the 309 samples analyzed for fentanyl and its analogs, 306 re-
ulted negative ( < 0,010 ng/mg) and 3 samples were positive: one was
ositive only to Fentanyl (0,071 ng/mg), while the other two showed the
resence of the precursor 4-ANPP (0,012 e 0,074 ng/mg), which is con-
idered either a metabolite or a precursor or fentanyl ( Salomone et al.,
020 ). 
When analyzed for oxycodone, the 309 samples tested negative in
03 cases ( < 0,300 ng/mg) and 6 samples were confirmed as positive
range: 0,304 - 9,350 ng/mg). 
Tramadol was screened in 189 samples: 177 resulted negative ( <
,100 ng/mg) and 12 resulted positive (range: 0,100 - 33,860 ng/mg).
esults from screening and confirmation analyses are summarized in
able 1 . A detailed summary of all positive findings for common drugs
f abuse and synthetic opioids is shown in Table 2 . Quite remarkably,
ll subjects positive to at least one among fentanyl, oxycodone and tra-
adol, also tested positive to methadone. 
iscussion and conclusion 
From a quantitative perspective, data emerging from our research do
ot seem to be alarming, as these molecules prevalence settles at around
nly 1% of our screened population. However, some considerations are
eeded. 
Of the three patients that tested positive to fentanyl, one was pos-
tive only to this molecule, while the other two showed, respectively,
resence also of tramadol and of both oxycodone and tramadol. 3 On the other hand, all other samples which resulted positive to either
xycodone or tramadol resulted negative for the fentanyl and analogs.
he concentrations obtained for oxycodone and tramadol are suggestive
f a frequent use, while the fentanyl concentration is more likely pro-
uced by sporadic exposure to the substance. In two cases, the precursor
r metabolite 4-ANPP was detected, either because fentanyl was below
he LOD, or because an analog of fentanyl was ingested by the tested
ndividual. 
In most cases, the use of oxycodone and tramadol was known to our
ddiction Center professionals, as the users had previously declared the
se for analgesic purposes and under regular medical prescription. These
atients were treated for Opioids Use Disorder (as diagnosed according
o the DSM 5) for several years (average age was 44,5 yrs for oxicodone-
ositive patients and 40,2 yrs for tramadol-positive patients) and over
ime they had established a trustful relationship with our team ( Table 3 ).
Contrarily, the three patients who resulted positive to fentanyl were
ery young (average age 26,3 yrs) and were admitted to the Addiction
nit of Trento only recently. The diagnosis for these users was opioid
ddiction, too, but their clinical courses were suggestive of multi-drugs
buse. The use of fentanyl had not been declared to the doctor, lead-
ng our team to at least three considerations: the first is that, probably,
he recent contact with our Unit and the health workers did not allow
 complete disclosure of users’ habits, nor a proper therapeutic rela-
ionship based on trust and communication; the second is that young
eople tend to abuse multiple substances at the same time ( Daneceau et
l. 2019 ; Maremmani et Al. 2009 ; Bersani et Al., 2013 ) underestimat-
ng the possible risks; the third one is that fentanyl and its derivatives
re becoming to be commonly used especially among young people for
ecreational purposes. 
A fourth, possible explanation, is that the subjects were not aware
f having taken fentanyl. This scenario is quite realistic since street sub-
tances are possibly replaced with counterfeit products. 
The positivity of the samples was communicated to the interested
atients: a common tendency to minimize the risks and to overestimate
heir ability to control the use of this drugs emerged. Unlike older pa-
ients, who tend to distrust new molecules and be cautious towards new
rends, young users also showed a propensity to “experiment ” with new
ubstances, even without fully knowing their properties and associated
isks. 
These considerations disclose an alarming scenario: although, based
n our sample, synthetic and pharmaceutical opioids use seems limited
n numbers, the dangerous patterns of use and the lack of awareness
mong young patients requires serious consideration by health profes-
ional. 
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Table 3 
Information about patients. 
Gender Age Diagnosis Scholarity 
Pharmacotherapy 
At the time of 
evaluation 
Duration of 
drug abuse Comorbidity 
Familiarity with 
drug abuse 
Male 38 Opioids (heroine) Use 
Disorder 
Graduation Methadone 5 years NO NO 




Methadone 1 year NO NO 






1 year Generalized Anxiety 
Disorder 
Alcohol Use Disorder 
(father) 
Male 26 Opioids (heroine)Use 
Disorder 
High School Diploma Methadone 3 years NO Opioid (heroine) Use 
Disorder (brother) 






40 years Major Depressive 
Disorder 
NO 
Male 26 Opioids (heroine) and 
Alcohol Use Disorder 
Middle School 
Diploma 
Methadone 1 year NO NO 




Methadone 43 years NO NO 
Female 50 Opioids (heroine) Use 
Disorder 
High School Diploma Methadone 12 years Major Depressive 
Disorder 
NO 
Male 29 Opioids (heroine) Use 
Disorder 
High School Diploma Methadone 3 years NO NO 






28 years Bipolar Disorder 
type 2 
Gambling Disorder 
(father) and Alcohol 
Use Disorder 
(mother) 
Female 52 Opioids (heroine) and 
Alcohol Use Disorder 
High School Diploma Methadone 
Escitalopram 
Zolpidem 
20 years Major Depressive 
Disorder 
NO 
Male 42 Opioids (heroine) 
Alcohol Use Disorder 
High School Diploma Methadone 
Bromazepam 
5 years Generalized Anxiety 
Disorder 
NO 




Buprenorphine 9 years NO NO 




Methadone 3 years NO NO 
Male 34 Opioids (heroine) and 
Cocaine Use Disorder 
Middle School 
Diploma 
Methadone 18 years NO NO 
Male 42 Opioids (heroine) and 
Alcohol Use Disorder, 
Gambling disorder, 
High School Diploma Methadone 
Mirtazapine 
8 years Major Depressive 
Disorder 
Alcohol Use Disorder 
(father) 




Methadone 1 year NO NO 




















































In fact, the opioid abuse epidemic often stems from over-prescribing
hese drugs in chronic pain by physicians without considering the re-
ated risks. Since opioid analgesics can be addictive, the physicians
ust give the patients all the information about the potential for abuse.
pioid analgesics shouldn’t be taken for longer than 3 to 6 months
o avoid the risk of iatrogenic addiction. General Practitioners are
ometimes unaware of this phenomenon, for this reason, we believe
hat sharing with colleagues is essential to reduce the spread of this
pidemic. 
Legally opioid analgesics are only available by prescription of a doc-
or, however in recent years the abuse of these drugs have increased
rimarily through two means: the illegal online sales on the black mar-
et and a method known as “diversion ”, when the drugs, prescribed
egally, are then passed or sold on to third party users. About 4% of the
dult US population misuses prescription opioids, and in 2015, more
han 33,000 deaths were attributable to overdose with licit and illicit
pioids ( Skolnick, 2018 ). 
Unauthorized online pharmacies sell drugs even without prescrip-
ions. These drugs are very often counterfeit, produced by clandestine
aboratories, contaminated by added substances and are therefore dan-
erous and often deadly. 
More information, better communication, and accurate sharing of
ews on Fentanyl, its derivatives and in general on all Novel Psychoac-
ive Substances are needed. Novel Psychoactive Substances can be def-
nite as a new narcotic or psychotropic drug, in pure form or in prepa-
ation, that is not controlled by the United Nations drug conventions,4 ut which may pose a public health threat as other illegal Substances
 EMCDDA, 2021 ). 
Information must be shared not only between health professionals
nd users, but also among specialist services, hospitals and general prac-
itioners, who are often the first prescribers of opioid analgesics or the
rst contacts for users developing an Opioid Use Disorder. Further atten-
ion should be paid to illicit manufactures and selling sites, in order to
revent the spread of the severe social and health consequences linked
o such use. This is certainly a great challenge for the future, in which
linicians and researchers must commit and believe. 
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